학술논문
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus
Document Type
Academic Journal
Author
Chen, Ji-Li; Dawoodji, Amina; Tarlton, Andrea; Gnjatic, Sacha; Tajar, Abdelouahid; Karydis, Ioannis; Browning, Judy; Pratap, Sarah; Verfaille, Christian; Venhaus, Ralph R.; Pan, Linda; Altman, Douglas G.; Cebon, Jonathan S.; Old, Lloyd L.; Nathan, Paul; Ottensmeier, Christian; Middleton, Mark; Cerundolo, Vincenzo
Source
International Journal Of Cancer. Mar 15, 2015 136(6):E590-E601
Subject
Language
English
ISSN
0020-7136
Abstract
WHATʼS NEW?: Cancer vaccines using genetically-engineered viruses have not been as successful as originally hoped. In this study, the authors asked whether first priming the immune system with antigen alone might improve the success of a viral vector. Melanoma patients were given priming injections of an antigen called NY-ESO-1 plus ISCOMATRIX adjuvant. Several patients who then received injections of a fowlpox virus encoding NY-ESO-1 had improved CD8+ T-cell responses, compared to no improvement in patients who simply received more of the isolated antigen.